Menu
Back to Journals » International Journal of Women's Health » Volume 1
Current status of maintenance therapy for advanced ovarian cancer
Published 2 November 2009 Volume 2009:1 Pages 173—180
DOI https://doi.org/10.2147/IJWH.S4661
Review by Single anonymous peer review
Peer reviewer comments 2
Joanie Mayer Hope, Stephanie V Blank
New York University School of Medicine, Division of Gynecologic Oncology, New York NY, USA
Abstract: Even after countered with and responding to maximal surgical and chemotherapy efforts, advanced ovarian cancer usually ultimately recurs. One strategy employed to forestall recurrence is maintenance chemotherapy, an extension of treatment following a complete response to conventional measures. Many agents have been studied and many more are currently under investigation in maintenance regimens. While phase III data suggest that taxane maintenance prolongs progression-free survival, no overall survival benefit has been established. This article reviews the current status of maintenance therapy for advanced ovarian cancer, including phase III evidence and new and upcoming trials.
Keywords: maintenance therapy, consolidation therapy, advanced ovarian cancer
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.